Cytogenetic abnormalities in CD34 cells and LTCICs
| Patient . | Cytogenetics . | Aneuploid cells in total BM, % . | Aneuploid CD34 cells, % . | Aneuploid cells in LTCICs, % . |
|---|---|---|---|---|
| 13-150 | 47,XX,+8 | 35 | ND | 48 |
| 2 | 47,XX,+8 | 25 | 20 | 4 |
| 3 | 47,XX,+8 | 15 | ND | 20 |
| 4 | 45,XX,−7 | 44 | 48 | 39 |
| 5 | 45,XX,−7 | 4 | ND | 10 |
| Patient . | Cytogenetics . | Aneuploid cells in total BM, % . | Aneuploid CD34 cells, % . | Aneuploid cells in LTCICs, % . |
|---|---|---|---|---|
| 13-150 | 47,XX,+8 | 35 | ND | 48 |
| 2 | 47,XX,+8 | 25 | 20 | 4 |
| 3 | 47,XX,+8 | 15 | ND | 20 |
| 4 | 45,XX,−7 | 44 | 48 | 39 |
| 5 | 45,XX,−7 | 4 | ND | 10 |
ND indicates not done.
Samples of BM were placed in long-term culture for 5 weeks as described in “Patients, materials, and methods”; colonies were harvested and FISH was performed. Additional samples were stained with CD34-PE and sorted by flow cytometry, and FISH was performed on CD34+cells. LTCIC percentages were based on at least 200 cells counted; CD34 percentages were based on at least 50 cells counted.
Patient with prior aplastic anemia receiving CsA.